- Home
- OKUR vs VANI Comparison
OKUR vs VANI Comparison
Compare OKUR & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- VANI
- Stock Information
- Founded
- OKUR 2011
- VANI 1998
- Country
- OKUR United States
- VANI United States
- Employees
- OKUR N/A
- VANI N/A
- Industry
- OKUR
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- OKUR
- VANI Health Care
- Exchange
- OKUR NYSE
- VANI Nasdaq
- Market Cap
- OKUR 75.5M
- VANI 70.5M
- IPO Year
- OKUR N/A
- VANI 2014
- Fundamental
- Price
- OKUR $5.74
- VANI $1.17
- Analyst Decision
- OKUR Strong Buy
- VANI Strong Buy
- Analyst Count
- OKUR 4
- VANI 1
- Target Price
- OKUR $35.00
- VANI $3.00
- AVG Volume (30 Days)
- OKUR 135.4K
- VANI 95.4K
- Earning Date
- OKUR 02-14-2025
- VANI 03-25-2025
- Dividend Yield
- OKUR N/A
- VANI N/A
- EPS Growth
- OKUR N/A
- VANI N/A
- EPS
- OKUR N/A
- VANI N/A
- Revenue
- OKUR N/A
- VANI N/A
- Revenue This Year
- OKUR N/A
- VANI N/A
- Revenue Next Year
- OKUR N/A
- VANI N/A
- P/E Ratio
- OKUR N/A
- VANI N/A
- Revenue Growth
- OKUR N/A
- VANI N/A
- 52 Week Low
- OKUR $4.58
- VANI $1.01
- 52 Week High
- OKUR $20.00
- VANI $7.80
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- VANI 41.87
- Support Level
- OKUR N/A
- VANI $1.15
- Resistance Level
- OKUR N/A
- VANI $1.23
- Average True Range (ATR)
- OKUR 0.00
- VANI 0.04
- MACD
- OKUR 0.00
- VANI -0.00
- Stochastic Oscillator
- OKUR 0.00
- VANI 45.31
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.